Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAM-3001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 0.01mg/kg and 0.03mg/kg CAM-3001 |
| 2 | ACTIVE_COMPARATOR | 0.1mg/kg CAM-3001 |
| 3 | ACTIVE_COMPARATOR | 0.3mg/kg CAM-3001 |
| 4 | ACTIVE_COMPARATOR | 1.0mg/kg CAM-3001 |
| 5 | ACTIVE_COMPARATOR | 3.0mg/kgCAM-3001 |
| 6 | ACTIVE_COMPARATOR | 10.0mg/kg CAM-3001 |
| 7 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CAM-3001 | DRUG | A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg. |
| Placebo | OTHER | Active: Placebo 5:1 for arms 2-6 |
Inclusion Criteria: * Signed and dated informed consent, prior to any study related procedures * Male and female patients aged 18-70 years at the screening visit * Use of an appropriate method of contraception * A diagnosis of adult onset rheumatoid arthritis of at least 6 months duration as define...
Top 20 of 28 competitors
CAM-3001 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being studied for safety and efficacy in patients.
CAM-3001 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's potential in treating rheumatoid arthritis.
CAM-3001 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and tolerability in patients with rheumatoid arthritis.
CAM-3001 has one completed clinical trial, identified as NCT00771420, titled 'A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis.' This Phase 1 study enrolled 38 participants in Germany and was placebo-controlled and double-blind.
CAM-3001 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for rheumatoid arthritis. The drug has completed a Phase 1 trial, but further studies are needed before it can be considered for regulatory approval.
CAM-3001 is an investigational small molecule being developed by AstraZeneca PLC for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development, with one completed trial (NCT00771420) that enrolled 38 patients in Germany.